drugset / Trial / NCT01367873

Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects

NCT01367873

Phase 1 Completed 72 enrolled Madrigal Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a single-center, randomized, double-blind, placebo-controlled, ascending single-dose study of VIA-3196 to evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects. Study dosing is organized into cohorts corresponding to escalating doses of VIA-3196 or matching placebo.

Timeline

Start
2011-06
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Resmetirom Small molecule Oral

Indications

No indication recorded.